Abstract The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is involved in immune function and cell growth; genetic variation in this pathway could influence breast cancer risk. We examined 12 genes in the JAK/STAT/SOCS signaling pathway with breast cancer risk and mortality in an admixed population of Hispanic (2,111 cases, 2,597 controls) and nonHispanic white (1,481 cases, 1,585 controls) women. Associations were assessed by Indigenous American (IA) ancestry. After adjustment for multiple comparisons, JAK1 (three of ten SNPs) and JAK2 (4 of 11 SNPs) interacted with body mass index (BMI) among pre-menopausal women, while STAT3 (four of five SNPs) interacted significantly with BMI among post-menopausal women to alter breast cancer risk. STAT6 rs3024979 and TYK2 rs280519 altered breast cancer-specific mortality among all women. Associations with breast cancerspecific mortality differed by IA ancestry; SOCS1 rs193779, STAT3 rs1026916, and STAT4 rs11685878 associations were limited to women with low IA ancestry, and associations with JAK1 rs2780890, rs2254002, and rs310245 and STAT1 rs11887698 were observed among women with high IA ancestry. JAK2 (5 of 11 SNPs), SOCS2 (one of three SNPs), and STAT4 (2 of 20 SNPs) interacted with cigarette smoking status to alter breast cancer-specific mortality. SOCS2 (one of three SNPs) and all STAT3, STAT5A, and STAT5B SNPs significantly interacted with use of aspirin/NSAIDs to alter breast cancer-specific mortality. Genetic variation in the JAK/ STAT/SOCS pathway was associated with breast cancerspecific mortality. The proportion of SNPs within a gene that significantly interacted with lifestyle factors lends support for the observed associations.
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The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is involved in immune function and cell growth and differentiation [1, 2] . The JAK family consists of four non-receptor protein tyrosine kinases, JAK1, JAK2, JAK3, and TYK2. Of these, JAK1, JAK2, and TYK2 are expressed ubiquitously in mammals [3] . Once activated by cytokines, JAKs serve as docking sites for signaling molecules such as STATs. Activated STATs translocate from the cytoplasm to the nucleus where they increase the transcription rate of several genes. STAT1 and STAT2 were first identified as contributing to activation of genes involved in immune response [4] . STAT5 was first described in the mammary gland and has considerable specificity for mammary gland development [5] . Altogether, seven STATS have been identified in mammalian cells, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 [6] . STAT signaling has been shown to be important for mammary cell survival and tumorigenesis [6] . It also has been suggested that expression of STATs is associated with unique breast cancer subtypes defined by estrogen receptor (ER) and progesterone receptor (PR) status [7] .
Cytokines up-regulate suppressors of cytokine signaling (SOCS) that inhibits the activity of JAKs and STATs [8] . Thus, research targeting an understanding of the JAK/ STAT/SOCS signaling pathway often has involved the interaction between JAK/STAT/SOCS with cytokines. STAT1 and STAT2 were first identified from work involving downstream events of receptor binding of interferon c (IFNc) on transcriptional activation of genes involved in immune response [4] . Pro-inflammatory cytokines such as IL-6 have been shown to up-regulate STAT proteins [4, 9, 10] . Both JAK1 and JAK2 are important for cytokines through use of the shared receptor subunits; IL-6 is an important pro-inflammatory cytokine that uses these receptors since they are essential for cytokine signaling [11] . JAK2 is essential for hormone-like cytokine signaling, including prolactin signaling [11] .
This study builds on our previous work that has evaluated breast cancer associations with genetic variants in cytokines among women with diverse genetic ancestry. We have shown that breast cancer risk and mortality as well as risk were associated with IL6, and other cytokine SNPs were different by Indigenous American (IA) ancestry [12, 13] . Thus, it is reasonable to hypothesize that breast cancer associations with genetic variation in JAK/STAT/SOCS genes may also vary by IA ancestry. Given previous work suggests that these genes may have unique ER/PR associations, we evaluated associations by ER/PR tumor subtype. Additionally, we evaluated the association of these genes with survival since one of their functions is to promote cell differentiation and metastases [14] . Since diet and lifestyle factors that are associated with inflammation may modify associations with these genes, we evaluate interaction of these genes with a dietary oxidative balance score, body mass index (BMI), cigarette smoking status, and use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).
Methods
The Breast Cancer Health Disparities Study includes participants from three population-based case-control studies [15] , the 4-Corners Breast Cancer Study (4-CBCS) [16] , the Mexico Breast Cancer Study (MBCS) [17] , and the San Francisco Bay Area Breast Cancer Study (SFBCS) [18, 19] , who completed an in-person interview and who had a blood or mouthwash sample available for DNA extraction. Information on exposures was collected up to the referent year, defined as the calendar year before diagnosis for cases or before selection into the study for controls. 4-CBCS participants were between 25 and 79 years; MBCS participants were between 28 and 74 years; and SFBCS participants were between 35 and 79 years. All participants signed informed written consent prior to participation; the Institutional Review Board for Human Subjects at each institution approved the study.
Data harmonization
Data were harmonized across all study centers and questionnaires as previously described [15] . Women were classified as either pre-menopausal or post-menopausal based on responses to questions on menstrual history. Pre-menopausal women were those who reported still having periods during the referent year. Post-menopausal women were those who reported either a natural menopause or if they reported taking hormone therapy (HT) and were still having periods or were at or above the 95th percentile of age for those who reported having a natural menopause (i.e.,[12 months since their last period). Women in 4-CBCS and SFBCS were asked to selfidentify their race/ethnicity and were classified as non-Hispanic white (NHW), Hispanic, Native American (NA), or a combination of these groups. Women in MBCS were not asked their race or ethnicity and were combined with U.S. Hispanics/NAs in the analyses.
Lifestyle variables including BMI were calculated as self-reported weight (kg) during the referent year divided by measured height squared (m 2 ) and categorized as normal (\25 kg/m 2 ), overweight (25-29.9 kg/m 2 ), or obese (C30 kg/m 2 ). Regular cigarette smoking was evaluated as current, former, or never where regular was defined as having smoked one or more cigarettes for 6 months or longer in 4-CBCS and SFBCS (data available for a subset of subjects only) or having smoked 100 or more cigarettes in MCBCS. A dietary oxidative balance score (DOBS) that included nutrients with anti-or prooxidative properties was used [20] . Dietary information was collected via a computerized validated diet history questionnaire in 4-CBCS [12, 21] , a 104-item semi-quantitative Food Frequency Questionnaire (FFQ) in MBCS [22] , and a modified version of the Block Food Frequency Questionnaire in SFBCS [23] . Alcohol consumption was based on long-term use; consumption during the referent year was used for a subset of SFBCS women without information on long-term use. Regular use of aspirin or NSAIDS defined as use for three or more times a week for at least 1 month was available for the 4-CBCS only. A history of diabetes was defined as ever being told by a health care provider that you had diabetes or high blood sugar (not available for all SFBCS participants).
Genetic data
DNA was extracted from either whole blood (n = 7,287) or mouthwash (n = 634) samples. Whole genome amplification (WGA) was applied to the mouthwash-derived DNA samples prior to genotyping. TagSNPs were selected to characterize the genetic variation using the following parameters: linkage disequilibrium (LD) blocks were defined using a Caucasian LD map and an r 2 = 0.8; minor allele frequency (MAF) [ 0.1; range = -1,500 bps from the initiation codon to ?1,500 bps from the termination codon; and one SNP/LD bin. Additionally, 104 Ancestry Informative Markers (AIMs) were used to distinguish European and Indigenous American (IA) ancestry [15] . All markers were genotyped using a multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San Diego, CA, USA). In the current analysis, we evaluated tagSNPs for JAK1 (10 SNPs), JAK2 (11 SNPs), SOCS1 (two SNPs), SOCS2 (three SNPs), STAT1 (15 SNPs), STAT2 (two SNPs), STAT3 (five SNPs), STAT4 (20 SNPs), STAT5A (two SNPs), STAT5B (three SNPs), STAT6 (six SNPs), and TYK2 (four SNPs). Online Supplement 1 provides a description of these genes and SNPs; Online Supplement 2 describes LD structure of these genes.
Tumor characteristics and survival
Data on estrogen receptor (ER) and progesterone receptor (PR) tumor status and survival were available for cases from 4-CBCS and SFBCS only. Cancer registries in Utah, Colorado, Arizona, New Mexico, and California provided information on stage at diagnosis, months of survival after diagnosis, cause of death, and ER and PR status. Surveillance Epidemiology and End Results (SEER) disease stage was categorized as local, regional, or distant.
Statistical methods

Genetic ancestry estimation
The program STRUCTURE was used to estimate individual ancestry for each study participant assuming two founding populations [24, 25] . A three-founding population model was assessed but did not fit the population structure. Participants were classified by level of percent IA ancestry (B28, , and [70 %), based on the distribution of genetic ancestry in the control population [15] .
SNP associations
Genes and SNPs were assessed for their association with breast cancer risk overall, by strata of IA ancestry, by menopausal status in the whole population, and by ER/PR status for the 4-CBCS and SFBCS. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Logistic regression models were used to estimate odds ratios (OR) and 95 % confidence intervals (CI) for breast cancer risk associated with SNPs, adjusting for study, BMI in the referent year, and parity as categorical variables and age (five-year categories) and genetic ancestry as continuous variables. Associations with SNPs were assessed assuming a co-dominant model. Based on the initial assessment, SNPs that appeared to have a dominant or recessive mode of inheritance were evaluated with those inheritance models in subsequent analyses. For stratified analyses, the p value was based on the Wald Chisquare test comparing the homozygote rare to the homozygote common when presenting the co-dominant model. The multinomial p value reported for ER/PR status using the glogit link in the logistic procedure compares unique associations by tumor phenotype. Adjustments for multiple comparisons within the gene used the step-down Bonferroni correction, taking into account, the degree of correlation of the SNPs within genes using the SNP spectral decomposition method was proposed by Nyholt [26] and modified by Li and Ji [27] . An unadjusted p value of\0.05 was considered statistically significant; results are presented for those where the multiple comparison adjusted p value was \0.15 and are noted as being marginally associated. 
Interactions
We assessed gene by environment interactions for lifestyle factors that could influence candidate genes given their potential involvement in inflammation, including BMI (separately for pre-and post-menopausal women given differences in risk associated with BMI by menopausal status), smoking (current, former, or never smokers), dietary oxidative balance score (DOBS), and regular use of aspirin/NSAID (for 4-CBCS participants only). DOBS was based on each individual's intake of anti-oxidants (vitamin C, vitamin E, beta carotene (data for beta carotene were not available for MBCS), folic acid, and dietary fiber) and prooxidants (alcohol). Nutrients were evaluated per 1,000 calories, and the DOBS was based on study-specific distributions given the different dietary questionnaires used. Alcohol consumption was classified into three levels: the top 25th percentile of consumption, all other drinkers, and non-drinkers. The DOBS ranges from low levels (first quartile) of exposure to anti-oxidants or high exposure to pro-oxidants (fourth quartile) to high levels of anti-oxidants (fourth quartile) and low exposure to pro-oxidants (non-drinkers). Tests for interactions were evaluated using Wald one degree of freedom (1-df) Chi-square tests.
Survival analysis
Survival months were calculated based on month and year of diagnosis and month and year of death or last contact. Survival updates were received in the winter of 2014 that included complete survival surveillance through December of 2012. Associations between SNPs and breast cancerspecific mortality among cases with a first primary invasive breast cancer were evaluated using Cox proportional hazards models to obtain multivariate hazard ratios (HR) and 95 % confidence CI. Individuals were censored when they died of causes other than breast cancer or were lost to follow-up. We present Wald p values for all women and by ancestry strata based on the comparison between the homozygote rare and common genotype when presenting the co-dominant inheritance model using models adjusted for age, study center, genetic ancestry, and SEER stage. Since survival data were not available for MBCS, the upper two ancestry strata were combined to evaluate survival by genetic ancestry. Interactions between genetic variants and genetic ancestry, BMI, cigarette smoking, DOBS, and aspirin/NSAID use with survival were assessed using p values from 1-df Wald Chi-square tests.
Results
The majority of women were U.S. Hispanic or Mexican and were slightly younger than U.S. NHW women (Table 1) . U.S. Hispanic women were more likely to have ER-/PR-tumors than NHW women. Approximately, 20 % of women had died, with 47.6 % of deaths being from breast cancer among NHW and 55.9 % of deaths among U.S. Hispanic women. Few associations were observed between SNPs in our candidate genes and breast cancer risk (Table 2) . STAT5B rs6503691 and TYK2 rs280519 were associated with reduced risk among women with high IA ancestry (OR CT/ TT = 0.63 95 % CI 0.41, 0.97, P het = 0.39 and OR AG/ GG = 0.75 95 % CI 0.58, 0.96, P het = 0.46), and STAT6 rs3024974 (OR CT/TT = 1.15 95 % CI 1.02, 1.29, P het = 0.71) was associated with increased breast cancer risk overall. More associations were observed for specific tumor phenotype, with JAK2 rs1536800 being associated with ER-/PR-tumors and STAT3 (four SNPs) and STAT5A (two SNPs) and STAT5B (one SNP) associated with ER-/PR? tumors. These differences were statistically significant for JAK2 rs1536800 (P het = 0.03), STAT3 rs8069645 (P het = 0.03), STAT5A 7217728 (P het = 0.04), and STAT5B rs7218653 (P het = 0.02). No significant differences in association were detected by menopausal status (data not shown). BMI was the main lifestyle factor that interacted with these genes to alter risk of breast cancer (Table 3) . JAK1 (three SNPs) and JAK2 (four SNPs) interacted with BMI among pre-menopausal women, with the majority of the differences observed among those who were obese. Among post-menopausal women, STAT3 (four SNPs) interacted with BMI to alter breast cancer risk, with the majority of the differences observed among those with normal BMI. Additionally, interactions were seen between STAT1 (two SNPs) and STAT4 (one SNP) and DOBS. We also assessed interaction between IL6 and its receptor and JAK/STAT/ SOC pathway genes and observed several significant interactions although after adjustment for multiple comparisons, none of the associations were statistically significant (data not shown).
STAT6 rs3024979 and TYK2 rs280519 were associated with breast cancer-specific mortality overall (Table 4) . However, most associations were restricted to either low or high IA ancestry group. Among women with low IA ancestry, SOCS1 rs193779, STAT3 rs1026916, and STAT4 rs11685878 were associated with breast cancer-specific mortality. Among women with high IA ancestry (JAK1 rs2780890, rs2254002, and rs310245) and STAT1 rs11887698 were associated with breast cancer-specific mortality. Additionally, JAK2 (five SNPs), SOCS2 (one SNP), and STAT4 (two SNPs) interacted with cigarette smoking status to alter breast cancer-specific mortality (Table 5) , with associations predominantly observed among current smokers. STAT1 rs2030171 and STAT5B rs9900213 interacted with DOBS to alter breast cancerspecific mortality (Table 5 ). Interactions also were seen between SOCS2 (one SNP), STAT3 (five SNPs), STAT5A (two SNPs), and STAT5B (three SNPs) and regular use of aspirin/NSAIDs. No significant interactions with BMI were observed after adjustment for multiple comparisons.
Discussion
Among genes within the JAK/STAT/SOC signaling pathway, we observed several associations between SNPs and breast cancer mortality and a few significant associations with risk of breast cancer, irrespective of genetic ancestry, or ER/PR tumor subtypes. However, lifestyle factors that influence inflammation interacted with these genes to alter breast cancer risk and mortality. Specifically, BMI and DOBS interacted with these genes to alter breast cancer risk, while cigarette smoking and aspirin/NSAID use interacted with them to influence breast cancer-specific mortality. The proportion of SNPs within a gene that significantly interacted with DOBS and lifestyle factors was considerably greater than by chance, lending support for the observed associations.
Although it is reasonable to hypothesize that genes could help explain differences in breast cancer incidence rates when comparing populations with high versus low IA ancestry, our results provide little support for that hypothesis. Others have suggested that this pathway has unique associations with tumor phenotype and estrogen [7, [28] [29] [30] ], but we found minimal support for differences in associations by ER/PR subtype. The majority of associations were with ER-/PR? tumors, and although statistically significant after adjustment for multiple comparisons, there were few individuals with that phenotype; therefore, estimates of association were imprecise even though they were statistically significant. Of interest are the consistent associations observed for the interaction of BMI with JAK1 (three out of ten SNPs) and JAK2 (4 out of 11 SNPs) for pre-menopausal breast cancer risk and with STAT3 (four of five SNPs) for postmenopausal breast cancer risk. The number of SNPs within genes that were associated with breast cancer risk was greater than one would expect by chance. One explanation for the interactions between BMI and JAK1, JAK2, and STAT3 could be the strong correlation between leptin and BMI. Although leptin is mainly produced by white adipocytes, it is also produced by mammary epithelium. The leptin receptor is a class I cytokine receptor that acts through JAK and STATs, and the JAK/STAT pathway is one of the main signaling cascades activated by leptin [31] . Additionally, STAT3 specifically has been shown to influence energy homeostasis [32, 33] . Activation of the JAK/STAT pathway also can promote tumor growth and induce inflammation as well as regulate other genes that control cell proliferation, differentiation, tumor development, and cell survival. The JAK/STAT pathway is critical for cell development, cell survival, cell proliferation, and apoptosis; our results suggest that genetic variation in these genes is important for breast cancer-specific mortality. We observed stronger estimates of association and more consistent associations across genes, and SNPs within those genes, with breast cancer-specific mortality than with breast cancer risk. Thus, it is possible that these genes function as tumor promoters, as has been suggested [6, 34] . The strongest and most consistent associations were observed for the interaction between cigarette smoking and aspirin/ NSAID use with JAK2, STAT3, STAT5a, and STAT5b and to a lesser extent with SOSC2 (rs3816997 which interacted with both cigarette smoking and aspirin/NSAIDs use) to influence breast cancer-specific mortality. The JAK/STAT signaling pathway is activated when cytokines are bound to their receptors, while SOCS suppresses the signaling. Nicotine has been shown to activate the JAK2/STAT3 pathway [35] , which in this case appears to promote tumor progression depending on JAK2/STAT3 genotype.
Regular use of aspirin/NSAIDs interacted with all SNPs evaluated for STAT3 (5), STAT5A (2), and STAT5B (3) to alter breast cancer-specific mortality. STAT3 has been shown to be a promoter of tumor invasiveness and angiogenesis [6] . Activation of STAT5, which was first recognized as mammary gland factor, results in regulation of several genes involved in cell apoptosis, survival, and proliferation [14] . It has been shown that aspirin regulates apoptosis by down-regulating the IL6-STAT3 pathway [36] and that the epidermal growth factor induces COX2 through STAT5 signaling [37] thus providing biological support for our observations. We believe that these findings are unique and have found no reference to the importance of these genes in the literature or in GWAS studies of breast cancer. Our candidate pathway approach has enabled us to identified important genes based on their biological function. Furthermore our ability to evaluate interaction with diet and lifestyle factors has enhanced our understanding of these genes and how they influence breast cancer risk and mortality.
This study has both strengths and limitations. The population represents a large genetically diverse population that includes extensive data on diet and lifestyle factors along with genetic data, ER/PR status, and vital status. However, ER/PR status and vital status were available only for the U.S. based studies. We used a tag-SNP approach to characterize genetic variation in these genes, although other SNPs could be important that were not analyzed. We adjusted for multiple comparisons within our candidate genes, although we cannot exclude the possibility of chance observations. However, the number of SNPs within genes for which we observed associations further indicates that these observations may be more than chance findings. Nevertheless, we encourage others to replicate our findings, especially those that pertain to survival, given their implication for treatment modalities as has been suggested [38] .
In conclusion, our findings suggest that genetic variation in the JAK/STAT/SOCS signaling pathway is important for breast cancer-specific mortality. Of note is the consistent and stronger interaction observed between JAK2, SOCS2, STAT3, and STAT5 and cigarette smoking and use of aspirin/NSAIDs to modify breast cancer-specific mortality. Additionally, JAK1, JAK2, and STAT3 interacted with BMI to modify risk of developing breast cancer. Given the potential importance of these findings on modalities such as aspirin/NSAIDS to improve survival on a subset of women, replication of these findings in other populations is needed.
